
TNDM Stock Forecast & Price Target
TNDM Analyst Ratings
Bulls say
Tandem Diabetes Care is expected to see potential growth and profitability in the future due to their strong revenue and upcoming product launches, such as the Mobi Tubeless pump and expansion into the pharmacy channel. However, there are potential risks, such as competition and slow adoption, that may hinder this growth. With analysts setting a price target of $27, Tandem Diabetes Care has the potential for larger recurring revenue in the future, but may see a decrease in revenue in the short term due to their focus on the pharmacy channel.
Bears say
Tandem Diabetes Care is facing headwinds such as supplier shortages causing a slowdown in revenue growth, and the transition to a pay-as-you-go model and pharmacy channel is expected to negatively impact near-term revenue. While this shift may drive long-term growth potential, Tandem Diabetes faces competition in the AID market and will need to execute on new product introductions to maintain market share and drive revenue growth. Overall, the potential for sustained revenue growth and margin expansion is uncertain, leading to a negative outlook on the company's stock.
This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.
TNDM Analyst Forecast & Price Prediction
Start investing in TNDM
Order type
Buy in
Order amount
Est. shares
0 shares